30 closest matches · ranked by relevance
Myalgic Encephalomyelitis/Chronic Fatigue Syndrome · Chronic Fatigue Syndrome · Myalgic Encephalomyelitis
Primary: Change in Peak Oxygen Uptake (Peak VO2) Between the First and Second iCPET — 13.3; -40.3; 111.8 mL/min — p=0.043
Chronic Fatigue Syndrome
Primary: Cardiopulmonary Exercise Test (CPET) - ATVO2rel — 16.0; 10.6 mL/kg/min
Myalgic Encephalomyelitis · Chronic Fatigue Syndrome
Primary: Total Daily Symptom Score (TDSS) — 29.5; 28.7; 29.2; 31.3 units on a scale — p=0.011
Mitochondrial Diseases
Primary: Average TSST-induced Elevation in Cortisol — 37.44; 33.86; 42.83; 45.42 ng*min/mL
Fibromyalgia
Primary: Change in Ratio of Choline/ Creatine (CHO/CR) in the Brain From Baseline to 3 Hrs Post-endotoxin Administration — -.0021; -.0058 ratio
Chronic Fatigue Syndrome · Cognitive Impairments
Primary: Change in BRIEF-A — 21.38; 3.36 Scores on a scale — p=.005
Widespread Chronic Pain
Primary: Development of Chronic Widespread Pain Assessed by Questionnaire — 69; 77 Participants
MELAS Syndrome
Primary: Clinical Safety of TIV Vaccine — 4; 0; 0; 0 Participants
Myoclonus Epilepsies, Progressive
Primary: Number of Participants With Treatment-Related Adverse Events After Single Dose Treatment of AUT00201 Compared to Placebo — 5; 5 Participants
Myasthenia Gravis
Primary: To Determine the Effect of Acupuncture on Quality of Life in Patients With MG — 10.8; 9.4; 3.6; 8.3 score on a scale
Muscle Weakness
Primary: Percent Change in the Amplitude of Evoked Compound Muscle Action Potential by Electromyography Between the First to Fifth Response — 0 percent change
Mild Cognitive Impairment · Metabolic Syndrome
Primary: MoCA (Montreal Cognitive Assessment) — 28.38; 20.22 score on a scale — p=<0.0001
Multiple Sclerosis, Relapsing-Remitting
Primary: Fatigue at 28 Weeks — 56.50; 29.00; 55.00; 40.00 score on a scale
Multiple Sclerosis · Fatigue · Physical Activity
Primary: Daily Average Fatigue Intensity Score — 3.9; 4.4; 3.2; 2.3 units on a scale
Chronic Fatigue Syndrome
Primary: Change in Fatigue Impact Scale at 6 Weeks — -32.6; -1.5 units on a scale — p=< 0.05
Migraine Disorders
Primary: Percentage of Participants With Episodic Migraine (EM) or Chronic Migraine (CM) — 91.2; 8.8 percentage of participants
Post COVID-19 Condition · Long COVID
Primary: Change From Baseline to Week 13 in PROMIS Fatigue Score (T-Score) — 69.9; 69.4; -25.4; -25.8 T-Score — p=0.9851
Fatigue in Multiple Sclerosis
Primary: Modified Fatigue Impact Scale (MFIS) Score — 40.6; 41.3; 39.0; 38.6 score on a scale
Amyotrophic Lateral Sclerosis
Primary: Electrical Impedance Myography — 0.55 Coefficient of Variation
Neurofibromatosis 1
Primary: Mitochondrial Respiration Efficiency (as Measured by OCR). — 67.7167; 53.7000; 73.3358; 68.5789 picomole/minute — p=<0.01
Fibromyalgia · Neurocognition
Primary: Visual Analogue Scale for Pain — 59.4; 68.6; 58.5; 66.2 mm
Mild Cognitive Impairment · Herpes Simplex 1 · Herpes Simplex 2
Primary: Change in Standardized Uptake Value Ratio (SUVR) of (18F-Florbetapir PET) From Week 0 to Week 52. — 0.07; 0.08 Standardized Uptake Value Ratio
GNE Myopathy
Primary: Mean Area Under the Curve (AUClast) of Plasma ManNAc (Baseline-adjusted) — 7461; 9432 hr*ng/mL
Fibromyalgia
Primary: Pain Intensity Using Numeric Rating Scale — 5.12; 6.36; 6.62 units on a scale — p=0.045
Multiple Sclerosis
Primary: Change From Baseline in Fatigue Levels — 50.98; 56.88; 57.87 score on a scale
Heart Failure
Primary: Maximal Voluntary Quadriceps Force [% Change From Baseline] — -30; -5 percentage change
Fibromyalgia · Mitochondrial Diseases · Movement Disorders
Primary: Heart Rate Variability (Time Domain) — 0.92; 0.83 msec/msec — p=0.77
Pain · Fatigue
Primary: Short Form 36 (SF-36) Physical Component Summary (PCS) — 36.2; 39.0 Scores on a scale — p=0.487
Gulf War Syndrome
Primary: Concentration of Myoinositol in the Brain — 0.001260; 0.001205 Institutional Units (IU)
Fibromyalgia · Myofascial Pain Syndrome · Muscular Diseases
Primary: Functional Disability Inventory — 25.78; 24.10; 25.96; 21.83 score on a scale